2022 forecast: AI, Fintiv rule, Arthrex
Steve Heap / Shutterstock.com
The US Supreme Court has rejected an attempt by Intel to challenge the controversial NHK-Fintiv rule, the latest in a series of denials meted out to tech companies and generic drug makers seeking the same review.
The rest of this article is locked for subscribers only. Please login to continue reading.
If you don't have a login, you will need to purchase a subscription to gain access to this article, including all our online content. Please use this link and follow the steps.
For multi-user price options, or to check if your company has an existing subscription to us that we can add you to for FREE, please email Atif Choudhury at email@example.com
SCOTUS, NHK-Fintiv, Intel, Apple, Mylan, IPR, Unified Patents